DOCSLIB.ORG

Reactive Oxygen Species Insufficiency (ROSI) As the Basis for Disease Allowance and Coexistence

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Reactive Oxygen Species Insufficiency (ROSI) As the Basis for Disease Allowance and Coexistence Reactive Oxygen Species Insufficiency (ROSI) as the Basis for Disease Allowance and Coexistence: Extraordinary Support for an Extraordinary Theory VOLUME I (One) BY PROF. HON. RANDOLPH M. HOWES, M.D., Ph.D. Orthomolecular Surgical Scientist and Biochemist Contents of volumes I through III: Volume I (One) Pages 1-530 of original: pp 501 Sections 1.0-1.9.0.4 Volume II (Two) Pages 531-1018 of original: pp 505 Sections 1.9.0.5-11.1.3 Volume III (Three) Pages 1019-1564 of original: pp 562 Sections 11.1.4-20.0.0 Unauthorized use of any of this material, without author permission, is prohibited by law. © 2008, Randolph M. Howes, M.D., Ph.D. Reactive Oxygen Species Insufficiency (ROSI) as the Basis for Disease Allowance and Coexistent: Extraordinary Support for an Extraordinary Theory Relationships between CANCER, ATHEROSCLEROSIS, DIABETES, OBESITY, HYPERTENSION, ARTHRITIS & CATARACTS (EMOD Insufficiency Syndrome of Howes) (EMODs) Electronically Modified Oxygen Derivatives THE HOWES SELECTIVE WORLD LIBRARY OF OXYGEN METABOLISM [The seventh in a series and a companion book to the following: #1. U.T.O.P.I.A. © 2004 Unified Theory of Oxygen Participation In Aerobiosis; #2. The Medical and Scientific Significance of Oxygen Free Radical Metabolism © 2005; #3. Hydrogen Peroxide Monograph 1: Scientific, Medical and Biochemical Overview & #4. Antioxidant Vitamins A, C, & E Monograph 2: Equivocal Scientific Studies, © 2006; #5. Cardiovascular Disease and Oxygen Free Radical Mythology, © 2006; #6. Diabetes and Oxygen Free Radical Sophistry, © 2006] A Selective World Literature Review Available at www.thepundit.com BY PROF. HON. RANDOLPH M. HOWES, M.D., Ph.D. Orthomolecular Surgical Scientist and Biochemist Adjunct Assistant Professor of Plastic Surgery, The Johns Hopkins Hospital, Baltimore, MD USA Espaldon Professor of Plastic and Reconstructive Surgery, University of Santo Tomas, Manila, Philippines Adjunct Professor of Biological Sciences, Southeastern Louisiana University Professor of Surgery, Biophysics and Biochemistry, Louisiana University of Medical Sciences Vice Chancellor/Dean, Louisiana University of Medical Sciences (Also holds an Honorary Doctorate of Humanities, SLU) Copyright © 2008 Free Radical Publishing Co. ISBN:1-885458-06-1 © 2008 by Randolph M. Howes M.D., Ph.D. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the written prior permission of the author. Notice to users: 1. User agrees not to redistribute any electronic artifacts of this resource without prior written permission from Free Radical Publishing Co. 2. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a data base or retrieval system, without prior written permission of the publisher. 3. It is understood that medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The author and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However in view of the possibility of human error or changes in the medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation of publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility to any errors or omissions or for the results obtained from use of the information contained in the work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs. Reactive Oxygen Species Insufficiency (ROSI) as the Basis for Coexistent Diseases: Extraordinary Support for an Extraordinary Theory Relationships between CANCER, ATHEROSCLEROSIS, DIABETES, OBESITY, HYPERTENSION, ARTHRITIS & CATARACTS (EMOD Insufficiency Syndrome of Howes) (EMODs) Electronically Modified Oxygen Derivatives TABLE OF CONTENTS Unauthorized use of any of this material, without author permission, is prohibited by law. © 2008, Randolph M. Howes, M.D., Ph.D. The U.T.O.P.I.A. Institute and Free Radical Publishing Co. 1.0 The Oxypocalypse 1.0.1 Prologue 1.0.2 Fundamental Value of Creative Ideas 1.0.3 DISCLOSURE AND DISCLAIMER 1.0.4 Introduction 1.0.4.1 The EMOD Insufficiency Syndrome of Howes or the ROSI Syndrome (Reactive Oxygen Species Insufficiency Syndrome) 1.0.4.2 Oxygen Factoids 1.0.5 Personal Introductory Comments: “Radical Planet” 1.0.6 Howes’ First Law 1.0.7 Howes’ Second Law 1.0.8 Howes’ Third Law 1.0.9 Howes’ Fourth Law 1.0.10 Howes’ Law of Cellular Biochemical Reactions 1.0.11 Howes’ Law of Risk of Infection 1.0.12 Howes’ Law of Common Chemistry 1.1.0 Antioxidant Vitamins, Free Radicals and Oxygen Myths 1.1.1 “Vitamine” History 1.1.2 The Antioxidant Myth: A Medical Fairy Tale – from New Scientist 1.1.3 Brief Primer on Oxygen Free Radicals: Current Misconceptions 1.1.3.1 Misconceptions Regarding SOD 1.1.3.2 Snapple’s New Antioxidant Water 1.1.4 Formation of Reactive Oxygen Species 1.1.5 Biological Effects of Reactive Oxygen 1.1.6 EMOD Production and Role 1.1.7 EMOD Sources and Control 1.1.8 Thomas L. Hesselink, MD: A Different Redox View 1.2.0 Most Biological Oxidants Arise from Superoxide 1.2.1.0 Superoxide the Evil 1.2.1.1 Antioxidant Enzyme 1.2.1.2 Low Molecular Weight Antioxidants 1.2.2.3 Superoxide the Good - 1.2.2.4 O2 Production by Phagocytes - 1.2.2.5 A Possible Antioxidant Activity of O2 Itself - 1.2.2.6 Regulation by O2 and H2O2 1.2.2.7 Conclusion 1.2.3.0 Oxygen Homeostasis 1.2.3.1 Heart Disease Predetermined by Oxygen Levels in the Womb 1.2.4.0 EMODs: General Information and Cardiovascular Disease 1.2.4.1 Producers and Destroyers of Reactive Oxygen Species 1.2.4.2 Xanthine Oxidoreductase 1.2.4.3 Nitric Oxide Synthase 1.2.4.4 Nitric Oxide Synthase, Nitrotyrosine Linked to Clustering of CVD and Other diseases 1.2.4.5 Superoxide Dismutases 1.2.4.6 Catalase 1.2.4.7 Glutathione Redox Cycle 1.2.4.8 ROS Scavengers 1.2.5.0 Arteries and Veins: A Comparison of Structure and Function 1.2.5.1 Vascular EMOD Metabolism 1.2.5.2 NADPH Oxidases 1.2.5.3 Xanthine Oxidase 1.2.5.4 NOS 1.2.5.5 SODs 1.2.5.6 So-called Oxidative Stress and Disease 1.2.5.7 Atherosclerosis 1.2.5.8 Hypertension 1.2.6.0 Three Mutations Control Hypertension 1.2.6.1 Novel Sources of EMODs in Humans 1.2.6.2 Functional Role of Nox and Duox EMOD Producers 1.2.6.3 EMOD Level Determines Brain Temperature Regulation/Fever 1.2.6.4 EMOD Producing Methylene Blue Fights Off Alzheimer’s 1.2.6.5 Methylene Blue Generates EMOD Hydrogen Peroxide and Hydroxyl Radical 1.2.6.6 EMODS and Cellular Regulation 1.2.6.7 Cellular Regulation by Hydrogen Peroxide 1.2.6.8 Vasodilation HYDROGEN PEROXIDE 1.2.7.0 Hydrogen Peroxide and the Peroxisome 1.2.7.1 Hydrogen Peroxide Produced by Lung Epithelial Cells 1.2.7.2 Hydrogen Peroxide Unexpectedly Benefits Airways 1.2.7.3 Inhibiting Stress Oxidant May Be New Therapy for COPD 1.2.7.4 More cellular Regulation by Hydrogen Peroxide 1.2.8.0 Hydrogen Peroxide and Endothelial Function 1.2.8.1 Sources of EMODs in Mammalian Cells 1.2.8.2 Questionable Role of Peroxide in Vascular Disease 1.2.8.3 Nitric Oxide and Natural Anti-cancer Activity 1.2.8.4 Insulin Stimulation also Induces the Production of Intracellular H2O2 1.2.8.5 Hydrogen Peroxide in Urine and Aqueous Humor 1.2.8.6 Ascorbate Autoxidation Produces H2O2 1.2.8.7 EMODs and Spermatozoa 1.2.8.8 Alleged Diseases Associated with EMODS VITAMINS 1.2.9.0 US Vitamin Sales 1.2.9.1 Vitamin Preferences 1.2.9.2 US Overview 1.2.9.3 Vitamin C as a Prooxidant 1.2.9.4 Vitamin C and Iron Co-supplementation Decrease LDL Oxidation and Platelet Aggregation 1.2.9.5 Antioxidant Vitamins May Raise LDL Levels 1.2.9.6 Meta-analysis of Vitamin C Heart Benefits 1.2.9.7 Vitamin E as a Prooxidant ANTIOXIDANTS 1.2.9.8 Superoxide Dismutase (SOD) as a Prooxidant 1.2.9.9 Impaired Antioxidant Defense System (SOD) of Colonic Tissue and Cancer Development in Dextran Sulfate Sodium-induced Colitis in Mice 1.3.0.0 Glutathione (GSH) as a Prooxidant 1.3.0.1 So-called Antioxidants (Polyphenolics) have Prooxidant Activity 1.3.0.2 Prooxidant Activity of Vitamins C, E, Carotenoids and Flavonoids 1.3.0.3 Prooxidant Activity of Polyphenolic Antioxidant (GSPE) Grape Seed Extract 1.3.0.4 Green Tea EGCG Activates Prooxidant-induced Apoptosis 1.3.0.5 Black Tea Antioxidants Show No Impact on Cardiovascular Risk Factors 1.3.1.0 Risks and Safety of Polyphenol Consumption: [Antioxidants: Isoflavones, Quercetin, Citrus Flavonoids, Resveratrol, Punicalagin (an Ellagitannin Present in Pomegranate Juice), Green Tea Catechins, Vitexin (a C-glycosylflavone), Proanthocyanidins (Condensed Tannins) and Ellagitannins, etc.] PROCEEDINGS OF THE 1ST INTERNATIONAL CONFERENCE ON POLYPHENOLS AND HEALTH 1.3.1.1 Immune Function and EMODs 1.3.1.2 Antioxidants 1.3.1.3 Comment of Balz Frei 1.3.1.4 Failed Antioxidant Studies of Brown et al.
Load more

Recommended publications
  • Validation of the PATHOGENA Electron-Activated Reactor For
    ineering ng & E P l r a o c i c e m s Opoku-Duah et al., J Chem Eng Process Technol 2015, 6:3 e s Journal of h T C e f c h o DOI: 10.4172/2157-7048.1000239 l ISSN: 2157-7048 n a o n l o r g u y o J Chemical Engineering & Process Technology CommentryResearch Article OpenOpen Access Access Validation of the PATHOGENA Electron-Activated Reactor for Purifying Contaminated Water in the Parkersburg Area in West Stephen Opoku-Duah*, Gordon Wells1, Wycliff Kipkomoi1, Ashley Wilcox1, Dennis Johnson2 and Mark Wiley3 1Ohio Valley University College of Arts and Sciences, Ohio Valley University, 1 Campus View Drive, Vienna, WV 26105 2EcH2O International Group, 14 Inverness Drive East, Suite D-112, Englewood, CO 80138 3TCG Global, 14104 E. Davies Ave., Suite B, Centennial, CO 80112 Abstract This paper concerns validation of the PATHOGENA version of electron-activated reactors designed to purify contaminated water to make it potable. The basic design of PATHOGENA is a 100-gallon plastic tank batch reactor which houses a vapor-ion plasma (VIP) generator and 1-micron ion-separator (ION-SEP) porous water filter. While the VIP generator splits ambient air into aggressive water treatment agents in the form of charged ions, free electrons, hydroxyl and peroxyl radicals using UV radiation, the ION-SEP filter is designed to eliminate broad-spectrum bacteria and other microbes. The validation process was started with creation of water quality database from: (a) contaminated surface water; (b) EPA/West Virginia Water Quality Standards, and (c) Vienna City Council drinking water.
    [Show full text]
  • Schedule 14A
    QuickLinks -- Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material under §240.14a-12 Verastem, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ý No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: o Fee paid previously with preliminary materials. o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    [Show full text]
  • Progress in the Chemistry of Dihydrogen Trioxide (HOOOH)
    Acta Chim. Slov. 2005, 52, 1–12 1 Review Article Progress in the Chemistry of Dihydrogen Trioxide (HOOOH) Božo Plesničar Department of Chemistry, Faculty of Chemistry and Chemical Technology, University of Ljubljana, P.O.Box 537, 1000 Ljubljana, Slovenia, E-mail: [email protected] Received 23-02-2005 Abstract During the past 15 years, there has been considerable progress in understanding of the chemistry of dihydrogen trioxide (HOOOH). In this account, the preparation, characterization and structure (1H, 17O NMR, IR, quantum chemical methods), kinetics and mechanism of decomposition, and reactivity of this simplest of polyoxides are discussed. Dihydrogen trioxide is, in organic oxygen bases as solvents, far more stable than previously believed. For example, the half-life of HOOOH in acetone-d6 is 16 ± 2 min; however, it decomposes rather quickly in water solutions (t1/2 ≈ 20 ms) at room temperature. HOOOH is most likely involved in oxidation processes that span atmospheric, environmental, and biological systems. Key words: ozone, low-temperature ozonation, dihydrogen trioxide HOOOH, density-functional theory, ab-initio, molecular-structure, hydrogen-bonds, HOOO anion, HOOO radical, alkyl hydrotrioxides ROOOH, thermal- decomposition Contents Introduction ...............................................................................................................1 Origins of Dihydrogen Trioxide Chemistry .............................................................1 Direct Spectroscopic Detection of Dihydrogen Trioxide ......................................2
    [Show full text]
  • WO 2016/074683 Al 19 May 2016 (19.05.2016) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/074683 Al 19 May 2016 (19.05.2016) W P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/10 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/DK20 15/050343 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 11 November 2015 ( 11. 1 1.2015) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (25) Filing Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: PA 2014 00655 11 November 2014 ( 11. 1 1.2014) DK (84) Designated States (unless otherwise indicated, for every 62/077,933 11 November 2014 ( 11. 11.2014) US kind of regional protection available): ARIPO (BW, GH, 62/202,3 18 7 August 2015 (07.08.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: LUNDORF PEDERSEN MATERIALS APS TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, [DK/DK]; Nordvej 16 B, Himmelev, DK-4000 Roskilde DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (DK).
    [Show full text]
  • Synthesis and Photochemistry of Pt(Iv) Hydroxo Complexes
    SYNTHESIS AND PHOTOCHEMISTRY OF PT(IV) HYDROXO COMPLEXES A Dissertation presented to the Faculty of the Graduate School at the University of Missouri – Columbia In Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy by LASANTHA ANURANGANA WICKRAMASINGHE Prof. PAUL R. SHARP, Dissertation Supervisor May 2015 (Chapter 2) Reproduced with permission from Lasantha A Wickramasinghe.; Sharp, P. R. Inorganic Chemistry, 2014, 53, 1430. Copyright © 2014 American Chemical Society (Chapter 3) Reproduced with permission from Lasantha A Wickramasinghe.; Sharp, P. R. Journal of American Chemical Society, 2014, 136, 13979. Copyright © 2014 American Chemical Society (Chapter 4) Reproduced with permission from Lasantha A Wickramasinghe.; Sharp, P.R. Inorganic Chemistry 2014, 53, 11812. Copyright © 2014 American Chemical Society (Chapter 4) Reproduced with permission from Lasantha A Wickramasinghe.; Sharp, P. R. Organometallics, 2015, under review. Copyright © 2015 American Chemical Society © Copyright by Lasantha A Wickramasinghe 2015 All Rights Reserved The undersigned, appointed by the dean of the Graduate School, have examined the dissertation entitled SYNTHESIS AND PHOTOCHEMISTRY OF PT(IV) HYDROXO COMPLEXES presented by Lasantha A Wickramasinghe, a candidate for the degree of doctor of philosophy, and hereby certify that, in their opinion, it is worthy of acceptance. Prof. Paul R. Sharp Prof. Timothy E Glass Prof. Justin R. Walensky Prof. Sheila Baker To my dear academic parents who encouraged me throughout my life ACKNOWLEDGEMENTS I wish to express my gratitude to Prof. Paul. R. Sharp. I would wholeheartedly thank him for giving me an opportunity to become one of this graduate students. Since I met Prof. Sharp in Sri Lanka, I have been given enormous support and the guidance to uplift my carrier in science.
    [Show full text]
  • Schedule 14A
    QuickLinks -- Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material under §240.14a-12 Verastem, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ý No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: o Fee paid previously with preliminary materials. o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    [Show full text]
  • Multiwell Thermodynamics Database-2019.1
    MULTIWELL THERMODYNAMICS DATABASE J. R. Barker, T. L. Nguyen, J. F. Stanton, C. Aieta, M. Ceotto, F. Gabas, T. J. D. Kumar, C. G. L. Li, L. L. Lohr, A. Maranzana, N. F. Ortiz, J. M. Preses, J. M. Simmie1, J. A. Sonk, and P. J. Stimac MultiWell-2017 Software Suite University of Michigan, Ann Arbor Michigan, 48109-2143, USA http://clasp-research.engin.umich.edu/multiwell/ Last revised: 4 March 2018 A database of species properties such as zero-point corrected electronic energies, vibrational frequencies, rotational constants, etc which are necessary in the calculation of the thermochemistry of chemical compounds and the kinetics of chemical reactions. Although the input datafiles listed below are formatted specifically towards the Multiwell suite of applications this data is just as useful for other purposes. Units and Standard State Units In this document the enthalpy of formation at 0 K, DfH(0) or dHf(0), and at 298.15 K, DfH(298), and the enthalpy function H(T)-H(0), are in kJ/mol whilst entropy and specific heat are in J/K/mol. The units of molecular properties are various but are specified in each datafile. Standard state 1 bar = 100,000 Pa or 100 kPa ideal gas. 1 JMS thanks the Irish Centre for High-End Computing, ICHEC, for the provision of computational resources, ngche041c. Page 1 of 77 Contents Units and Standard State ............................................................. 1 Datafile structure ................................................................... 6 Examples ............................................................................
    [Show full text]
  • GLOSSARY of CLASS NAMES of ORGANIC COMPOUNDS and REACTIVE INTERMEDIATES BASED on STRUCTURE (IUPAC Recommendations 1995)
    Pure &App/. Chem., Vol. 67, Nos 819, pp. 1307-1375, 1995. Printed in Great Britain. (B 1995 IUPAC INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY ORGANIC CHEMISTRY DMSION COMMISSION ON NOMENCLATURE OF ORGANIC CHEMISTRY (III. 1) COMMISSION ON PHYSICAL ORGANIC CHEMISTRY (III.2) GLOSSARY OF CLASS NAMES OF ORGANIC COMPOUNDS AND REACTIVE INTERMEDIATES BASED ON STRUCTURE (IUPAC Recommendations 1995) Prepared for publication by G.P. MOSS, P.A.S. SMITH and D. TAVERNIER Cornpodtion of the ZZZ.1 & 111.2 Working Party (1980-1994): H.J.T. Bos, A.J. Boulton, E.W. Godly, P. Griinanger, A.D. McNaught, G.P. Moss, R. PanicO, J. Rigaudy, P.A.S. Smith (Conwnorfiom ZZZ, I), J.H. Stocker, D. Tavernier, R.A.Y. Jones, J. March, J.M. McBnde, P. Miiller (Conwnorfim 111.2). Membership of the Commission on Nomenclature of Organic Chemistry during the preparation of this document (1980-1994) was as follows: Titular Members: 0. Achmatowicz (Poland) 1979-1987; H. J. T. Bos (Netherlands) 1987- , Vice-Chairman, 1991- ; J. R. Bull (Republic of South Africa) 1987-1993; H. A. Favre (Canada) 1989- , Chairman, 1991- ; P. M. Giles, Jr. (USA) 1989- ; E. W. Godly (UK) 1987-1993. Secretary, 1989-1993 ; D. Hellwinkel (Federal Republic of Germany) 1979-1987, Vice- Chairman, 1981-1987; B. J. Herold (Portugal) 1994- ; K. Hirayama (Japan) 1975-1983; M. V. KisakUrck (Switizrland) 1994- ; A. D. McNaught (UK) 1979-1987; G. P. Moss (UK) 1977- 1987, Chairinan, 1981- 1987, Vice-Chainnun, 1979-1981; R. Panico (Francc) 1981-1991, Vice- Chairman, 1989-1991; W. H. Powell (USA) Secretary, 1979-1989; J.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0309017 A1 Hassler Et Al
    US 2011 0309017A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0309017 A1 Hassler et al. (43) Pub. Date: Dec. 22, 2011 (54) METHODS AND DEVICES FOR ENHANCING CO2F I/44 (2006.01) CONTAMINANT REMOVAL BY RARE CO2F I/72 (2006.01) EARTHIS CO2F L/70 (2006.01) CO2F I/52 (2006.01) (75) Inventors: Carl R. Hassler, Gig Harbor, WA CO2F I/42 (2006.01) (US); John L. Burba, III, Parker, CO2F I/26 (2006.01) CO (US); Charles F. Whitehead, CO2F I/68 (2006.01) Henderson, NV (US); Joseph CO2F IOI/30 (2006.01) Lupo, Henderson, NV (US); CO2F IOI/2O (2006.01) Timothy L. Oriard, Issaquah, WA CO2F IOI/22 (2006.01) (US) CO2F IOI/12 (2006.01) CO2F IOI/14 (2006.01) (73) Assignee: MOLYCORP MINERALS, LLC, CO2F IOI/IO (2006.01) Greenwood Village, CO (US) CO2F IOI/38 (2006.01) CO2F IOI/16 (2006.01) (21) Appl. No.: 13/086,247 CO2F IOI/36 (2006.01) CO2F IOI/34 2006.O1 (22) Filed: Apr. 13, 2011 ( ) Related U.S. Application Data (52) U.S. Cl. ......... 210/638; 210/749; 210/753: 210/758: (60) Provisional application No. 61/323,758, filed on Apr. 210/757: 210/723; 210/668; 295.839; 13, 2010, provisional application No. 61/325,996, s filed on Apr. 20, 2010. Publication Classification (57) ABSTRACT (51) Int. Cl. Embodiments are provided for removing a variety of con CO2F I/00 (2006.01) taminants using both rare earth and non-rare earth-containing CO2F I/76 (2006.01) treatment elements.
    [Show full text]
  • Bio-IT World Conference & Expo
    Featured Presentations by: Platinum Sponsors: Font: Optima Regular Colors: Dark Blue #003399 (CMYK 96, 69, 3, 0) Light Blue #6699CC (CMYK 62, 22, 3, 0) ENABlING TECHNOlOGy. Leveraging Data. TransformING mEDICINE. CONCURRENT TRACKS: KEYNOTE PRESENTATIONS BY: 1 IT Infrastructure — Hardware 2 IT Infrastructure — Software John Halamka, m.D., m.S., Gold Sponsors: CIO, Harvard Medical School 3 Bioinformatics and Next-Gen Data 4 Systems and Predictive Biology 5 Cheminformatics and ARTISTS IN DATA STORAGE Computer-Aided Modeling Christoph Westphal, m.D., Ph.D., eClinical Trials Technology CEO, Sirtris Pharmaceuticals; 6 Senior Vice President, Centre of 7 eHealth Solutions Excellence for External Drug Discovery, GlaxoSmithKline Deepak Singh, Ph.D., EVENT FEATURES: Business Development Manager, Access All Seven Tracks for One Price Amazon Web Services Network with 1,500+ Attendees Hear 100+ Technology and Scientific Presentations Bronze Sponsors: Attend Bio-IT World’s Best KEYNOTE PANEL: Practices Awards The Future of Personal Genomics Connect with Attendees Using CHI’s Intro-Net A special plenary panel discussion featuring: Participate in the Poster Competition James Heywood, Co-founder and Chairman, PatientsLikeMe See the Winners of the following Dan Vorhaus, J.D., M.A., Attorney, Robinson, Bradshaw & Hinson; 2010 Awards: Editor, Genomics Law Report Benjamin Franklin Dietrich Stephan, Ph.D., President & CEO, Ignite Institute Best of Show Kári Stefánsson, MD, Dr Med, Executive Chairman and President Best Practices of Research, deCODE genetics View Novel Technologies and Solutions in the Expansive Exhibit Hall Kevin Davies, Ph.D., Editor-in-Chief, Bio-IT World And Much More! And More... BIONETWORKS Corporate Support Sponsors Bio-ITWorldExpo.com Organized & Managed by: Official Publication: Cambridge Healthtech Institute 250 First Avenue, Suite 300, Needham, MA 02494 Phone: 781-972-5400 • Fax: 781-972-5425 • Toll-free in the U.S.
    [Show full text]
  • New Zealand Chemistry Olympiad Trust Training Group Selection Examination
    New Zealand Chemistry Olympiad Trust Training Group Selection Examination Wednesday 29 October 2014 TIME ALLOWED: 120 minutes Answer ALL questions on this examination booklet Calculators may be used The marks for the twelve (12) questions sum to 100 A periodic table with atomic masses is also provided STUDENT’S NAME:______________________________________ STUDENT’S EMAIL:_______________________________________________________ SCHOOL:___________________________________________________ Question 1 2 3 4 5 6 7 8 9 10 11 12 Total /8 /4 /12 /5 /12 /10 /7 /6 /5 /12 /13 /6 /100 Mark QUESTION ONE (8 marks) There are three isomers of C5H12. (a) Draw the structure of each isomer. (b) One of the alkane isomers from part (a) reacts with Cl2 in the presence of light to give a single monohalogenated organic product. Draw the structure of that product. (c) Another one of the isomers from part (a) reacts with Cl2 in the presence of light to give four different monochloro alkanes. One of these is a secondary chloroalkane. (i) Draw the structure of this chloroalkane. (ii) Draw the structures of alkenes produced when the secondary chloroalkane from part (i) reacts with KOH in ethanol. (iii) Circle the alkene from part (ii) above that is formed in the greatest amount. Justify your answer. QUESTION TWO (4 marks) There are five C5H10 constitutional (structural) isomers that are alkenes. (a) One of the five alkenes exists as cis-trans stereoisomers. Draw the structure of the cis isomer of this alkene. (b) Explain why the alkene in part (a) exists as cis-trans isomers whereas the isomeric alkene that has the same carbon skeleton does not.
    [Show full text]
  • IUPAC Provisional Recommendations
    Preferred IUPAC Names 291 Chapter 6, Sec P-68 September, 2004 P-68 Nomenclature of organic compounds of the Groups 13, 14, 15, 16, and 17 elements not included in Sections 62-67. P-68.0 Introduction P-68.1 Nomenclature of compounds of Group 13 P-68.2 Nomenclature of compounds of Group 14 P-68.3 Nomenclature of compounds of Group 15 P-68.4 Nomenclature of compounds of Group 16 P-68.5 Nomenclature of compounds of Group 17 P-68.0 Introduction The nomenclature of organic compounds is based on two approaches. General principles, rules and conventions are applicable, with some rare exceptions, to all compounds belonging to Groups 13 through 17. They have been described and illustrated in previous Chapters. Another approach is based on the identical treatment of compounds within one Group. Up until now the nomenclature of compounds of Group 13 was essentially that of boron compounds. The nomenclature of aluminium, gallium, indium and thallium compounds in these recommendations has been modeled on that of boron compounds. It is thus advantageous to describe all compounds of a Group, to clearly identify their similarities and underline exceptions, if any. This way should facilitate the naming of new compounds by comparison with established models. Another aspect of nomenclature described Group by Group is to easily grasp the general patterns of the different Groups. The nomenclature of Group 15 is diversified. Suffixes are associated with nitrogen; mononuclear and polynuclear acids are the base of many derivatives of phosphorus, arsenic and antimony compounds; bismuth compounds are all named substitutively.
    [Show full text]